Considered Problem, Kimia Farma Stop Distribution Of Biozek Rapid Test

JAKARTA - The state-owned pharmaceutical company, PT Kimia Farma Tbk, has temporarily stopped the distribution of biozek rapid test, which is a product and manufacture of Dutch Inzek International Trading BV.

This termination is the aftermath of the findings of the investigation by the Tempo team and the Organized Crime and Corruption Reporting Project (OCCRP) in their reporting that the device was manufactured in China and had very low accuracy.

"PT Kimia Farma Tbk took steps, namely asking Inzek International Trading BV Netherlands for clarification on the news, temporarily stopping the distribution of rapid tests while waiting for the results of clarification from producers," said Kimia Farma Corporate Secretary Change Winarno Putro in a written statement received by VOI. , Wednesday May 13.

Kimia Farma stated that it has been importing and distributing biozek rapid test products since mid-April 2020. Furthermore, the company stated that biozek rapid test products have been distributed to health service facilities, examination laboratory networks and provincial / district / city health offices.

"The company is always committed to providing the best health services and solutions for the community as well as carrying out procedures in accordance with the provisions, regulations and principles of Good Corporate Governance (GCG)," he said.

Initially, the company imported because the state-owned issuer believed that the product met legal requirements and obtained a certificate to be traded and commercialized in the European market.

Meanwhile, the product is claimed to have been used in developed countries such as the Netherlands, England, Portugal, Georgia, and Saudi Arabia.

To note, the biozek rapid test is a type of IVD antibody rapid test that is only used for screening tests and further testing is needed for diagnosis through the polymerase chain reaction (PCR) test method.